References
- Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K, Mat-suda T. Studies on Bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo). 1974;27:775–84.
- Ishikawa H. Mizolobine and mycophenolate Mofetil. Curr Med Chem. 1999;6:575–97.
- Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent development in molecular action and chemical application. Transplant Proc. 1998;1:89–90.
- Suthanthiran M, Morris RE, Strom TB. Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis. 1996;28:159–72.
- Hughes SE, Gruber SA. New immunosuppressive drugs in organ transplantation. J Clin Pharmacol. 1996;36:1081–92.
- Kokado Y, Ishibashi I, Jiang H. Low dose cyclosporine, miz-oribine and prednisolone in renal transplantation: a new triple therapy. Clin Transplant. 1990;4:191–7.
- Inoue T, Kusaba R, Takahashi I, Sugumoto H, Kuzuhara K, Yamada Y, et al. Clinical trial of Bredinine in renal transplan-tation. Transplant Proc. 1981;13:315–8.
- Shiokawa Y, Akizuki R, Yokohari R, Hashimoto H, Kashiwazaki S, Kondo H, et al. Clinical evaluation of mizoribine on rheu-matoid arthritis: a double-blind comparative study using lobe-nzariddisodium as a standard drug (in Japanese). Igakunoayumi. 1991;156:811–31.
- Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequency relapsing nephritic syndrome. Kidney Int. 2000;58:317–24.
- Kaneko K, Nagaoka R, Ohtomo Y, Yamashiro Y. Mizoribine for childhood IgA nephropathy. Nephron. 1999;83:376–7.
- Aihara Y, Miyamae T, Ito S, Kobayashi S, Imagawa T, Mori M, et al. Mizoribine as an effective combined maintenance therapy with prednisolone in childhood-onset systemic lupus erythema-tosus. Pediatr Int. 1999;19:2–11.
- Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Wada S. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin Nephrol. 2003;60:390–4.
- Fukunishi T, Takahashi S, Hashinaka Y, Oota K, Nagano S, Takada K, et al. Bredinine concentration in blood and immuno-suppressive effect (in Japanese). Ishyoku Jpn J Transplant. 1982;17(Suppl):750–2.
- Sonda K, Takahashi K, Tanabe K, Funchinose S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizori-bine in renal transplantation patients. Transplant Proc. 1996;28:3643–8.
- Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, et al. Miz-oribine therapy for patients with lupus nephritis: the association for peak mizoribine concentration and clinical efficacy. Mod Rheumatol. 2007;17:206–12.
- Shetty H, Gokal R. Peritoneal dialysis as the first-choice treat-ment. Ronco C, Dell'Aquila R, Rodighiero MP, editors. Perito-neal dialysis today. Contrib Nephrol. vol 140. Basel: Karger; 2003. p. 218–225.
- Japanese Society of Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec. 31, 2008. 2009:1-22 (in Japanese).
- Tanaka H, Old E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, et al. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku pediatric study group. Nephron Clin Pract. 2008;110:c73–9.
- Kasama T, Wakabayashi K, Odai T, Isozaki T, Matsunawa M, Yajima N, et al. Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate. Mod Rheumatol. 2009;19(4):395–400.
- Doi T, Masaki T, Shiraki N, Kawai T, Yorioka N. Oral mizori-bine pulse therapy for steroid-dependent focal segmental glo-merulosclerosis. Clin Nephrol. 2008;69:433–5.
- Ikezumi Y, Suzuki T, Karasawa T, Kawachi H, Nikolic-Paterson DJ, Uchiyama M. Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy. Pediatr Nephrol. 2008;23:645–50.
- Tsubouchi Y, Fukuda W, Kawahito K, Kohno M, Wada M, Ishino H, et al. A case of lupus nephritis improved after appro-priately adjusting the dosage of mizoribine. Mod Rheumatol. 2008;18:91–5.